Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: JohnP who wrote (580)	7/2/1998 9:09:00 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 1906

Firstly, Amgen is not unique among biotechs: other biotechs also make real, FDA-approved products that generate real revenue. Secondly, Amgen really has two big products and not much else: Epogen and Nupogen. Its approvals take the form of expanded label uses for these products. That doesn't take away from their success with these products, but the fact remains that aside from these drugs Amgen's pipeline consists of "promises of drugs or cures several years down the road." And Amgen's pipeline cupboard is pretty bare for a company with its size and science. Amgen could appreciate significantly, maybe even 50% - this will largely be contingent upon market conditions.